Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT04115488 is registered in ClinicalTrials.gov with Polpharma Biologics S.A. as lead sponsor.

NCT NCT04115488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04115488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
Lead sponsor
Polpharma Biologics S.A.
Phase
Phase 3
Overall status
Completed
Start date
October 1, 2019
Completion date
February 7, 2022
Enrollment
265 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis (rrms)